Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Pegylated Liposomal Doxorubicin-related Palmar-plantar Erythrodysesthesia ('hand-foot' Syndrome).

D. Lorusso, A. Di Stefano, V. Carone, A. Fagotti, S. Pisconti, G. Scambia
Published 2007 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Palmar-plantar erythrodysesthesia (PPE), also called hand-foot syndrome or hand-to-foot syndrome, is a distinctive and relatively frequent dermatologic toxic reaction associated with certain chemotherapeutic agents. Pegylated liposomal doxorubicin (PLD), a long-circulating formulation of doxorubicin in which doxorubicin hydrochloride is encapsulated within pegylated liposomes, is approved to treat patients with metastatic breast cancer, advanced ovarian cancer, and acquired immunodeficiency syndrome-related Kaposi's sarcoma. The incidence of PPE is increased in patients receiving PLD compared with conventional doxorubicin. In studies that utilized the currently approved dose of PLD (50 mg/m(2) every 4 weeks), approximately 50% of all patients receiving PLD experienced PPE, and approximately 20% experienced grade 3 PPE. The pathophysiology of PPE, as it occurs with any drug with which it is associated, is not well understood. Studies evaluating the development of PPE specifically associated with PLD have not fully elucidated the mechanism; however, data support the roles of drug excretion in sweat and local pressure as contributors. When PPE develops, clinical interventions with respect to altering PLD administration include dose reduction, less frequent dosing, and ultimately, drug withdrawal with several consequences on treatment efficacy. This article will review the available data regarding the etiology and potential management strategies of PPE associated with PLD.
This paper references
10.1006/GYNO.2001.6272
Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.
P. Rose (2001)
Chemotherapy-induced palmer planter erythrodysesthesia.
S. Bhasin (2005)
Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity
D Lorusso (2004)
Protective effect of amifostine (AMF) on Doxil/Caelyx-induced palmar-plantar erythrodysesthesia (PPE) in patients (pts) with advanced cancer
O Lyass (2001)
10.1016/J.YGYNO.2004.05.027
Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies.
R. Drake (2004)
10.1006/GYNO.2000.5980
The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.
S. Campos (2001)
Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile?
D. Lorusso (2004)
[Hand-foot syndrome with capecitabine therapy].
A. Marini (2007)
Use of ‘Bag Balm’ as topical treatment of palmar-plantar erythrodysesthesia syndrome (PPES) in patients receiving selected chemotherapeutic agents
SF Chin (2001)
Prevention of palmar-plantar erythrodysesthesia associated with liposome-encapsulated doxorubicin (Doxil) by oral dexamethasone
MA Titgan (1997)
10.1016/J.YGYNO.2004.02.019
The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma.
K. Molpus (2004)
Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model.
D. Vail (1998)
10.1023/A:1013574328938
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
C. Eng (2001)
10.7326/0003-4819-101-6-798
Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome.
J. Lokich (1984)
10.1002/cncr.21662
Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma
R. Rifkin (2006)
Effect of celecoxib on capecitabine-indiced hand-foot syndrome and antitumor activity. Oncology (Williston
E Lin (2002)
10.1007/s002800050981
Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia
A. López (1999)
10.1177/096032719901800103
Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs
M. Amantea (1999)
10.1200/JCO.2002.12.113
Dose-dense anthracycline-based chemotherapy for node-positive breast cancer.
G. Ellis (2002)
10.1200/JCO.1995.13.11.2851
Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study.
G. Bertelli (1995)
10.1038/144512A0
Vitamin B6 and Skin Lesions in Rats
P. György (1939)
10.1093/ANNONC/MDL079
Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.
J. Sehouli (2006)
10.1007/BF00216925
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion
C. Fabian (2004)
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
E. Lin (2002)
10.1007/s00105-006-1183-y
Hand-Fuß-Syndrom bei einem Patienten unter Capecitabin-Therapie
A. Marini (2006)
10.1006/GYNO.2000.5921
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
M. Markman (2000)
10.1093/ANNONC/MDI204
Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?
U. Jacobi (2005)
Palmar-plantar erythrodysestasia syndrome associated with 5-fluorouracil treatment.
A. Comandone (1993)
10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
O. Lyass (2000)
10.1124/JPET.103.053413
Multiple Injections of Pegylated Liposomal Doxorubicin: Pharmacokinetics and Therapeutic Activity
G. Charrois (2003)
10.1159/000251603
Erythematous eruption of the palms and soles associated with mitotane therapy.
R. Zuehlke (1974)
10.1016/S0749-2081(03)00059-7
Prevention and treatment of adverse effects related to chemotherapy for recurrent ovarian cancer.
S. J. Edwards (2003)
10.1093/ANNONC/MDH097
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
10.1200/JCO.2001.19.14.3312
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
A. Gordon (2001)
10.2165/00128071-200001040-00004
Antineoplastic Therapy—Induced Palmar Plantar Erythrodysesthesia (‘Hand-Foot’) Syndrome
E. Nagore (2000)
10.1200/JCO.1997.15.10.3185
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.
M. Ranson (1997)



This paper is referenced by
10.1016/j.jaip.2013.11.007
Indications, protocols, and outcomes of drug desensitizations for chemotherapy and monoclonal antibodies in adults and children.
D. Hong (2014)
10.1007/978-3-642-28044-3_8
Applications of Piezoelectricity in Nanomedicine
G. Ciofani (2012)
10.1007/5584_2018_328
Hand-Foot Syndrome and Progression-Free Survival in Patients Treated with Sunitinib for Metastatic Clear Cell Renal Cell Carcinoma.
J. Kucharz (2019)
Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer.
Y. Lu (2016)
Improving Anticancer Therapy with ELP-based Drug Delivery Systems
Eric M Mastria (2016)
A mini review on Oral dosage forms
P. Gayathri (2016)
10.1016/j.jconrel.2010.04.006
Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer.
S. Cai (2010)
10.4137/CMT.S4456
Pegylated Liposomal Doxorubicin in the Management of Ovarian Cancer
G. Ferrandina (2010)
10.1016/j.ctrv.2014.02.002
Bridging cancer biology and the patients' needs with nanotechnology-based approaches.
N. Fonseca (2014)
10.1371/journal.pone.0214545
Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency
Christina E. M. Schindler (2019)
10.4103/0378-6323.206233
Pegylated liposomal doxorubicin-induced miliaria crystallina and lichenoid follicular eruption
A. C. Seghers (2018)
10.1111/j.1610-0387.2008.06831.x
Skin toxicity of anti‐cancer therapy
J. Ulrich (2008)
10.1038/nnano.2007.387
Nanocarriers as an emerging platform for cancer therapy.
D. Peer (2007)
Reviews in Oncology Capecitabine Associated Hand-Foot Syndrome : A Review
E. U. Cidon (2010)
10.1111/j.1610-0387.2008.06831_supp.x
Hauttoxizität durch antitumorale Therapie
J. Ulrich (2008)
10.1038/ncomms15507
Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy
Y. Su (2017)
10.1007/s00280-019-03976-2
Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer
O. Kubeček (2019)
10.1016/j.breast.2014.02.005
Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).
A. Templeton (2014)
10.1016/j.jhsa.2015.10.001
Hand Problems Related to Chemotherapeutic Agents.
Beatrice L. Grasu (2015)
10.1200/JCO.2013.48.7470
Intertrigo-like dermatitis with pegylated liposomal doxorubicin: diagnosis and management.
Abeer Najem (2014)
10.1016/J.ANNDER.2008.05.012
Syndrome mains-pieds : nouvel effet secondaire de l’erlotinib
A. Rouxel (2008)
10.3389/fphar.2018.01358
Challenges and Opportunities of Nanotechnology as Delivery Platform for Tocotrienols in Cancer Therapy
Geetha Maniam (2018)
10.1016/j.toxlet.2016.11.024
The role of the ATM/Chk/P53 pathway in mediating DNA damage in hand-foot syndrome induced by PLD.
Jie Yang (2017)
We detail the arsenal of nanocarriers and molecules available for selective tumour targeting , and emphasize the challenges in cancer treatment
D. Peer (2007)
10.1016/j.jconrel.2019.05.030
Liposome and immune system interplay: Challenges and potentials.
Fahimeh Zahednezhad (2019)
10.1159/000351801
Efficient Prevention Strategy against the Development of a Palmar-Plantar Erythrodysesthesia during Chemotherapy
J. Lademann (2013)
10.1021/mp200522d
Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models.
L. M. Kaminskas (2012)
10.1016/j.jconrel.2015.01.033
Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinoma.
Eric M Mastria (2015)
10.1016/j.biopha.2017.09.059
A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer.
A. Shafei (2017)
10.1188/10.ONF.137-139
Hand-foot syndrome related to liposomal doxorubicin.
K. Swenson (2010)
10.1007/s00216-016-9641-6
Evaluation of cytotoxicity profile and intracellular localisation of doxorubicin-loaded chitosan nanoparticles
Gabriele Dadalt Souto (2016)
10.1111/vco.12342
Liposome-encapsulated chemotherapy: Current evidence for its use in companion animals.
B. Børresen (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar